Published in J Neurochem on September 01, 1980
Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol (2010) 1.89
Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction. Ann N Y Acad Sci (2010) 1.17
Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells. Cancer Res (2010) 0.91
Relevance of animal models to human tardive dyskinesia. Behav Brain Funct (2012) 0.83
Normal Striatal Vesicular Acetylcholine Transporter Expression in Tourette Syndrome. eNeuro (2017) 0.75
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature (2000) 4.68
Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature (1990) 2.80
Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem (2001) 2.63
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry (2011) 2.31
EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol (2010) 2.21
MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology (2004) 2.07
An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet (1999) 2.01
Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol (2000) 1.99
Rating of the lesions in senile dementia of the Alzheimer type: concordance between laboratories. A European multicenter study under the auspices of EURAGE. J Neurol Sci (1990) 1.96
Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA (1998) 1.76
Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet (1992) 1.76
The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler (2006) 1.71
Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol (2001) 1.64
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology (2009) 1.59
Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology (2010) 1.59
Effects of novelty and habituation on acetylcholine, GABA, and glutamate release from the frontal cortex and hippocampus of freely moving rats. Neuroscience (2001) 1.50
Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum Genet (2001) 1.50
The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Mult Scler (2009) 1.45
Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology (2004) 1.36
Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol (2007) 1.36
Missense mutation of S182 gene in Italian families with early-onset Alzheimer's disease. Lancet (1995) 1.28
Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet (1996) 1.26
Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology (2008) 1.21
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry (2012) 1.20
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology (2008) 1.19
Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur J Pharmacol (1984) 1.19
Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol (1999) 1.16
Investigations into the acetylcholine output from the cerebral cortex of the cat in the presence of hyoscine. Br J Pharmacol Chemother (1967) 1.15
Effect of psychoactive drugs on the output of acetylcholine from the cerebral cortex of the cat. Eur J Pharmacol (1968) 1.15
Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol (1983) 1.15
Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience (2005) 1.14
Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Pharmacol Biochem Behav (1996) 1.11
ApoE as a prognostic factor for post-traumatic coma. Nat Med (1995) 1.08
Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. Biochem Biophys Res Commun (1999) 1.08
A comparison of unawareness in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2007) 1.06
Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol (1996) 1.06
Alzheimer's disease: role of size and location of white matter changes in determining cognitive deficits. Dement Geriatr Cogn Disord (2005) 1.06
Abnormal platelet glutamate dehydrogenase activity and activation in dominant and nondominant olivopontocerebellar atrophy. Ann Neurol (1986) 1.03
Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment. Dement Geriatr Cogn Disord (2005) 1.03
Investigation on acetylcholine, aspartate, glutamate and GABA extracellular levels from ventral hippocampus during repeated exploratory activity in the rat. Neurochem Res (2003) 1.03
Effects of morphine on brain and spinal acetylcholine levels and nociceptive threshold in the frog. Brain Res (1974) 1.02
Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease. Neuroscience (1999) 1.01
The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ (2004) 1.01
Taurine distribution in cat brain. J Neurochem (1972) 1.00
Investigations into the adenosine outflow from hippocampal slices evoked by ischemia-like conditions. J Neurochem (1993) 0.99
Enhanced acetylcholine release in the hippocampus and cortex during acquisition of an operant behavior. Brain Res (1996) 0.99
Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Int J Immunopathol Pharmacol (2003) 0.99
The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience (2003) 0.98
EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol (2012) 0.95
Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience (1997) 0.95
Extracellular levels of amino acids and choline in human high grade gliomas: an intraoperative microdialysis study. Neurochem Res (2004) 0.94
A2 adenosine receptors: their presence and neuromodulatory role in the central nervous system. Gen Pharmacol (1996) 0.94
Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia. Eur J Pharmacol (1986) 0.94
Changes in cortical acetylcholine output induced by modulation of the nucleus basalis. Brain Res Bull (1986) 0.93
Effect of adenosine, adenosine triphosphate, adenosine deaminase, dipyridamole and aminophylline on acetylcholine release from electrically-stimulated brain slices. Neuropharmacology (1983) 0.93
Mutations in the open reading frame of the beta-site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer's disease. Neurogenetics (2001) 0.92
A1 and A2 adenosine receptors modulate acetylcholine release from brain slices. Eur J Pharmacol (1984) 0.92
Electrical stimulation of the stratum radiatum increases the release and neosynthesis of aspartate, glutamate, and gamma-aminobutyric acid in rat hippocampal slices. J Neurochem (1983) 0.92
Early structural changes in individuals at risk of familial Alzheimer's disease: a volumetry and magnetization transfer MR imaging study. J Neurol (2009) 0.92
Temporal correlation between adenosine outflow and synaptic potential inhibition in rat hippocampal slices during ischemia-like conditions. Brain Res (1998) 0.92
Regional differences in the electrically stimulated release of endogenous and radioactive adenosine and purine derivatives from rat brain slices. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.92
Effect of bicuculline and strychnine on the acetylcholine content of the amphibian spinal cord. Br J Pharmacol (1972) 0.92
Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis. Neuroscience (1995) 0.91
Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits. Ann N Y Acad Sci (1999) 0.91
NO synthesis inhibition decreases cortical ACh release and impairs retention of a conditioned response. Brain Res (2001) 0.91
Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis (2004) 0.90
Fidia and neuroscience. Nature (1993) 0.90
Serotonin blocks the long-term potentiation induced by primed burst stimulation in the CA1 region of rat hippocampal slices. Neuroscience (1992) 0.90
Metabolic correlates of executive dysfunction. Different patterns in mild and very mild Alzheimer's disease. J Neurol (2007) 0.90
Decrease of brain acetylcholine release in aging freely-moving rats detected by microdialysis. Neurobiol Aging (1988) 0.90
Education and occupation provide reserve in both ApoE ε4 carrier and noncarrier patients with probable Alzheimer's disease. Neurol Sci (2011) 0.90
Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. Hum Mol Genet (1998) 0.90
Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neurosci Lett (1999) 0.90
Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res (1999) 0.89
Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a multicenter Italian clinical cross-sectional study on 431 patients. Dement Geriatr Cogn Disord (2012) 0.89
Confirmation of association between expanded CAG/CTG repeats and both schizophrenia and bipolar disorder. Psychol Med (1996) 0.89
Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res (1997) 0.89
Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices. Br J Pharmacol (1999) 0.89
Effect of magnocellular forebrain nuclei lesions on acetylcholine output from the cerebral cortex, electrocorticogram and behaviour. Arch Ital Biol (1982) 0.89
Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 0.89
Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects. Mol Chem Neuropathol (1995) 0.88
Adenosine and memory storage: effect of A(1) and A(2) receptor antagonists. Psychopharmacology (Berl) (1999) 0.88
Administration of amyloid beta-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo. Brain Res (1994) 0.88
p66(shc) is highly expressed in fibroblasts from centenarians. Mech Ageing Dev (2005) 0.88
The release of acetylcholine from the brain: an approach to the study of the central cholinergic mechanisms. Prog Neurobiol (1973) 0.88
Muscarinic receptor modulation of acetylcholine release from rat cerebral cortex and hippocampus. Neurosci Lett (1995) 0.88
Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. Eur J Neurosci (2000) 0.87
Association between angiotensin-converting enzyme and Alzheimer disease. Arch Neurol (2000) 0.87
Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis. Br J Pharmacol (1991) 0.87
EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol (2015) 0.87